Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2026-06-12 16:26:49 ET · period of report 2026-06-10 · accession 0001918845-26-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-12 16:26 | 2026-06-10 | AVTX | Doyle Mittie | Chief Medical Off | F - Tax | $13.10 | -1,084 | 51.8K | -2% | -$14.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-10 | F | D | 1,084 | $13.10 | 51,776 | D | — | — | (F1) Includes 5,738 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |